Hympavzi 150 mg
As listed in the register: Hympavzi 150 mg, Injektionslösung im Fertigpen
150 mg ·
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Marstacimabum
- Used in
- Blood, clotting and anaemia
- Made by
- Pfizer AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Schwere Hämophilie A ohne Inhibitoren und schwere Hämophilie B ohne Inhibitoren
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Pfizer AG |
|---|---|
| Active substance | Marstacimabum |
| Used in | Blood, clotting and anaemia |
| Strength | 150 mg |
| Classification | B02BX11 · Blood, clotting and anaemia |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Hympavzi 150 mg, Injektionslösung im Fertigpen |
| Packs | 1 Stück |
| Zulassungsnummer | 69556 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.